Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adebrelimab + SHR2554
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Adebrelimab + SHR2554 is an investigational combination therapy consisting of adebrelimab, a humanized IgG4 monoclonal antibody targeting programmed death-ligand 1 (PD-L1), and SHR2554, an oral small molecule inhibitor of Enhancer of Zeste Homolog 2 (EZH2). Developed by Jiangsu Hengrui Pharmaceuticals, this regimen is being evaluated for its synergistic potential in treating hematologic malignancies. EZH2 inhibition is thought to remodel the tumor microenvironment and enhance the efficacy of PD-L1 blockade by increasing the expression of antigen-presenting genes and promoting T-cell infiltration. The combination is currently in Phase Ib/II clinical trials for relapsed or refractory peripheral T-cell lymphoma (PTCL) and NK/T-cell lymphoma (NKTCL).
- Other names
- adebrelimab and SHR2554SHR-1316 + SHR2554
02
Targets
EZH1CD274 (Programmed cell death protein 1 ligand 1)EZH2 (Histone-lysine N-methyltransferase EZH2)
Beyond the preview
Go deeper on adebrelimab + SHR2554.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adebrelimab + SHR2554.